TRIAMINIC-12
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIAMINIC-12 (TRIAMINIC-12).
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.
| Metabolism | Pseudoephedrine is partially metabolized in the liver by N-demethylation to norpseudoephedrine, with about 70-90% excreted unchanged in urine. Chlorpheniramine is extensively metabolized in the liver via CYP2D6 and other pathways, including N-demethylation and oxidative deamination. |
| Excretion | Triaminic-12 contains chlorpheniramine and pseudoephedrine. Chlorpheniramine: ~50% renal as metabolites, <1% unchanged. Pseudoephedrine: ~70-90% renal unchanged, remainder as metabolites. Total elimination: renal > 90%, fecal < 10%. |
| Half-life | Chlorpheniramine: 12-15 hours (terminal) in adults, extended in hepatic impairment or elderly. Pseudoephedrine: 5-8 hours (terminal) in adults with normal renal function, prolonged in renal impairment (up to 20 hours). The combination product's duration is determined by chlorpheniramine. |
| Protein binding | Chlorpheniramine: ~70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible binding (<10%). |
| Volume of Distribution | Chlorpheniramine: 3-4 L/kg (widespread distribution, including CNS). Pseudoephedrine: 2-3 L/kg (distributes into body tissues). |
| Bioavailability | Chlorpheniramine oral: ~25-50% due to first-pass metabolism (extensive hepatic CYP450). Pseudoephedrine oral: ~75-100% well absorbed, minimal first-pass. |
| Onset of Action | Oral: Chlorpheniramine onset 30-60 minutes; Pseudoephedrine onset 30-60 minutes. |
| Duration of Action | Chlorpheniramine: 4-6 hours for antihistamine effect, up to 12-24 hours for suppression of wheal/flare. Pseudoephedrine: 4-6 hours oral. The product's extended-release formulation provides up to 12 hours of symptom relief. |
Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-50 mL/min), reduce frequency to every 24 hours. No adjustment for mild impairment. |
| Liver impairment | Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, use with caution and consider reducing dose frequency to every 24 hours due to increased half-life. |
| Pediatric use | Not recommended for children under 12 years. For children 12 years and older, use adult dosing. |
| Geriatric use | For patients >65 years: use with caution due to increased risk of anticholinergic effects and potential for hypertension or tachycardia. Consider starting with 1 tablet every 24 hours and monitor response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIAMINIC-12 (TRIAMINIC-12).
| Breastfeeding | Acetaminophen is compatible with breastfeeding. Pseudoephedrine passes into breast milk (M/P ratio approximately 3.3) and may reduce milk supply; avoid if possible. Dextromethorphan has limited data but considered low risk. Chlorpheniramine is compatible but may cause drowsiness in infant. Overall, use with caution and monitor infant for sedation. |
| Teratogenic Risk | Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoephedrine is associated with a possible increased risk of gastroschisis in the first trimester; dextromethorphan has limited data but no clear teratogenic signal; chlorpheniramine is considered safe in pregnancy. FDA pregnancy category varies by component: acetaminophen B, pseudoephedrine C, dextromethorphan C, chlorpheniramine B. Overall, avoid in first trimester if possible due to pseudoephedrine. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component. Concomitant use with MAO inhibitors or within 2 weeks of discontinuing MAO inhibitors. Severe hypertension or coronary artery disease. Narrow-angle glaucoma. Urinary retention. Use in children under 12 years.
| Precautions | Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention. May cause dizziness or drowsiness; avoid alcohol and other CNS depressants. Do not exceed recommended dosage. Not for use in children under 12 years. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure due to pseudoephedrine; assess fetal heart rate if prolonged use. No specific fetal monitoring required for short-term use. Observe neonate for withdrawal if used near term (pseudoephedrine and chlorpheniramine). |
| Fertility Effects | Acetaminophen may slightly reduce male fertility with prolonged use. Pseudoephedrine and dextromethorphan have no known significant impact on fertility. Chlorpheniramine may cause anticholinergic effects, but no direct fertility impairment. |